Skip to main content
Drug costs

GLP-1 medications

Man preparing to use an auto injector syringe at a table.
OVERVIEW

Balancing the costs and benefits of GLP-1s

Drug benefits and costs of GLP-1 drugs.
White paper

Payer strategies for GLP-1 medications for weight loss

White paper

GLP-1 agonists in Medicaid: Utilization, growth, and management

Read the paperNavigation Arrow
White paper

Questions surrounding anti-diabetic GLP-1s in Medicaid

See our quantitative analysisNavigation Arrow
Insight

Read our latest research on GLP-1s

workers collaborating at laptop
Webinar

Slimming down costs: MFPs and anti-obesity models unpacked

Gain timely insights into the upcoming Medicare Part D Maximum Fair Prices (MFP) for 2026 and 2027. Explore how these changes will impact coverage, access, and the competitive landscape for generics and biosimilars. Plus, discover the transformative power of anti-obesity demonstration models and what they mean for the future of healthcare.

man opening prescription bottle
Report

Building a long-range GLP-1 forecast: When could commercial health plans see a plateau?

GLP-1 drugs: We provide a framework for building a long-range forecast to help employers understand how trends may change over time.

White paper

Measuring how GLP-1 medications impact the total cost of care

Approaches to assessing and managing the effects of GLP-1 drugs on health and financial outcomes

Products

Related Milliman products

Premium comparison platform
Cost-saving analysis

Milliman Specialty Pharmacy Insights

Learn moreNavigation Arrow
Healthcare analytics
Healthcare analytics

MedInsight

Learn moreNavigation Arrow

Services

Related Milliman services

Life sciences

Learn moreNavigation Arrow

Medicaid

Learn moreNavigation Arrow

Employer-sponsored health & group benefits

Learn moreNavigation Arrow

We’re here to help